Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Arthritis Care & Research|August 12, 2025
Identification of Adult Dermatomyositis Patients Using Real-World Data SourcesBenjamin Martin, Will Kelly, Hannah Morgan-Cooper, et al.
Global Public Health|September 6, 2013
Health system challenges of cardiovascular disease and diabetes in four Eastern Mediterranean countriesPeter Phillimore, Shahaduz Zaman, Balsam Ahmad, et al.
BMJ (Clinical Research Ed.)|June 21, 2022
Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort studyXintong Li, Anna Ostropolets, Rupa Makadia, et al.
Plos One|January 17, 2025
CohortDiagnostics: Phenotype evaluation across a network of observational data sources using population-level characterizationGowtham A Rao, Azza Shoaibi, Rupa Makadia, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|May 26, 2025
Variation in Phenotype Definitions in Observational Clinical Research: A Review of Three ConditionsAzza Shoaibi, Anna Ostropolets, James Weaver, et al.
JAMIA Open|November 29, 2023
Evaluating the impact of alternative phenotype definitions on incidence rates across a global data networkRupa Makadia, Azza Shoaibi, Gowtham A Rao, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2021
Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort studyAkihiko Nishimura, Junqing Xie, Kristin Kostka, et al.
Drug Safety|June 2, 2022
Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort StudyAzza Shoaibi, Gowtham A Rao, Erica A Voss, et al.
Frontiers in Pharmacology|October 3, 2022
International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patientsAkihiko Nishimura, Junqing Xie, Kristin Kostka, et al.
Ophthalmology. Retina|March 22, 2024
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network StudyCindy X Cai, Akihiko Nishimura, Mary G Bowring, et al.
Pageof 4